Estudo randomizado | Eficácia e segurança de longo prazo de ixekizumabe por até 108 semanas em pacientes pediátricos com psoríase moderada a grave.
19 Abr, 2022 | 12:16h
Comentário no Twitter
In this RCT, by 108 weeks of use of ixekizumab for pediatric psoriasis, PASI 75/90/100 were achieved in 92%/79%/55%, respectively, of children, with clearance of nails in 68%, scalp in 76%, genital lesions in 88%, and palm/sole involvement in 90%. https://t.co/vk73Z3MKi4
— JAMA Dermatology (@JAMADerm) April 13, 2022